home About Us People Portfolio News Contact Us Fund II Investor Login » Fund III Investor Login » Fund IV Investor Login »

TriVascular

$96 million

Medical Device
Cardiovascular

Oct26
2014
Endologix, Inc. and TriVascular Technologies, Inc. Announce Merger to Create a Leading Cardiovascular Growth Company Focused on the Treatment of Aortic Disorders »

Aug4
2014
TriVascular Technologies, Inc. Receives FDA Approval of the Ovation iX(TM) Abdominal Stent Graft System »

Aug4
2014
Trivascular Technologies, Inc. and CRG Modify Term Loan Agreement »

Jun15
2014
TriVascular Technologies, Inc. Announces FDA Approval of Ovation iX(TM) Iliac Stent Graft »

Nov10
2014
TriVascular Technologies, Inc. and CRG LP Amend and Restate Term Loan Facility »

Oct15
2014
TriVascular Announces FDA Approval of CustomSeal(TM) Technology for the Ovation Prime(R) System »

Apr29
2014
TriVascular Announces FDA-Approved Expansion of Ovation® and Ovation Prime™ Indication Statements »

Apr22
2014
TriVascular Technologies, Inc. Announces the Closing of Its Initial Public Offering »

Apr15
2014
TriVascular Technologies, Inc. Announces Pricing of Initial Public Offering »

SANTA ROSA, Calif., April 15, 2014 - TriVascular Technologies, Inc. (Nasdaq:TRIV), manufacturer of the Ovation Prime™ Abdominal Stent Graft System, today announced the pricing of its initial public offering of 6,500,000 shares of its common stock at a public offering price of $12.00 per share. In addition, TriVascular has granted the underwriters a 30-day option to purchase up to an additional 975,000 shares of common stock at the same price. The company's shares are expected to begin trading on The NASDAQ Global Select Market on April 16, 2014 under the ticker symbol "TRIV."

 

The offering is expected to close on April 22, 2014, subject to customary closing conditions.

 

J.P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC are acting as joint book-running managers for the offering. Canaccord Genuity Inc. and Stifel, Nicolaus & Company, Incorporated are acting as co-managers.

 

A registration statement relating to the securities being sold in this offering was declared effective by the Securities and Exchange Commission on April 15, 2014. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.

 

The offering will be made only by means of a prospectus. When available, copies of the final prospectus may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204, or from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, by telephone at (800) 221-1037 or by email at newyork.prospectus@credit-suisse.com.

 

About TriVascular Technologies, Inc.

TriVascular is a medical device company developing and commercializing innovative technologies to significantly advance minimally invasive treatment of abdominal aortic aneurysms. The company manufactures the Ovation Prime Abdominal Stent Graft System, the lowest profile FDA-approved system, which utilizes a novel, polymer-based sealing mechanism. TriVascular is based in Santa Rosa, California.

Nov18
2014
TriVascular Secures $40 Million in Equity Financing »

Feb5
2014
TriVascular and Capital Royalty Close Term Loan Facility »

Jan21
2014
TriVascular Receives U.S. FDA Approval for the Ovation Prime™ Abdominal Stent Graft System »